Dbaibo G, et al. - Researchers assessed the immunogenicity and safety of a quadrivalent meningococcal conjugated vaccine using tetanus toxoid (MenACWY-TT; a meningococcal vaccine targeting 4 of the 6 most prevalent serogroups) co-administered with routine vaccines in healthy infants. They assessed immune responses to MenACWY-TT in infants who received MenACWY-TT according to 3 schedules: 3+1 (at ages 2, 4, 6 and 15–18 months; group ACWY3+1); 1+1 (at 6 and 15–18 months; group ACWY1+1) or single-dose at 15–18 months (group ACWY1). They found that 3+1 (at ages 2, 4, 6, 15–18 months); 1+1 (6, 15–18 months) or 1-dose (15–18 months) MenACWY-TT schedules were immunogenic. Findings showed immunogenicity as well as good tolerability of primary vaccination with 3 or 1 dose(s) of MenACWY-TT when it was co-administered with routine pediatric vaccines in infants.